AI Analysis
AI-generated analysis. Always verify with the original filing.
IceCure Medical announced positive 5-year top-line results from the ICESECRET clinical trial of ProSense® cryoablation for small renal masses in kidney cancer patients, with 83.9% recurrence-free rate at median four-year follow-up overall and 89.4% in the subgroup with tumors ≤3 cm and no prior kidney cancer. The data supports broader commercial adoption of ProSense® in approved markets including the U.S. and Europe.
Key Takeaways
183.9% recurrence-free rate for general study population (112 patients evaluated) at median follow-up of four years (IQR 1.4–5.3)
289.4% recurrence-free rate in subgroup with tumors ≤3 cm, no prior kidney cancer, and successful initial procedures
3114 patients enrolled (138 lesions ≤5 cm) at Bnai Zion Medical Center and Shamir Medical Center, Israel
412 patients underwent second cryoablation at mean 1.73±1.2 years
5Full results to be presented at European Conference on Interventional Oncology 2026 in Basel, Switzerland, April 26-30
6ProSense® approved in U.S., Europe, and other markets for malignant and benign kidney tumors